MX362675B - Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina. - Google Patents
Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina.Info
- Publication number
- MX362675B MX362675B MX2015003772A MX2015003772A MX362675B MX 362675 B MX362675 B MX 362675B MX 2015003772 A MX2015003772 A MX 2015003772A MX 2015003772 A MX2015003772 A MX 2015003772A MX 362675 B MX362675 B MX 362675B
- Authority
- MX
- Mexico
- Prior art keywords
- grpr
- detection
- diagnosis
- treatment
- imaging
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 101150032569 Grpr gene Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 108010073466 Bombesin Receptors Proteins 0.000 abstract 2
- 102000047481 Gastrin-releasing peptide receptors Human genes 0.000 abstract 2
- 238000003384 imaging method Methods 0.000 abstract 2
- 239000000523 sample Substances 0.000 abstract 2
- 238000001506 fluorescence spectroscopy Methods 0.000 abstract 1
- 238000002595 magnetic resonance imaging Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012634 optical imaging Methods 0.000 abstract 1
- 238000002600 positron emission tomography Methods 0.000 abstract 1
- 238000002603 single-photon emission computed tomography Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un antagonista de GRPR radiomarcado de la fórmula general MC-S-P en donde: M es un radiometal y C es un agente quelante de metal que se une establemente a M; o MC es un Tyr- o un grupo prostético unido a un radiohalógeno, en donde M es el radiohalógeno; S es un PABZA-DIG separador covalentemente ligado entre C y P , en donde S está covalentemente unido a el N-terminal de P; y P (SEQ ID NO: 1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705513P | 2012-09-25 | 2012-09-25 | |
| PCT/US2013/061712 WO2014052471A1 (en) | 2012-09-25 | 2013-09-25 | Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015003772A MX2015003772A (es) | 2015-11-09 |
| MX362675B true MX362675B (es) | 2019-01-30 |
Family
ID=49887190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003772A MX362675B (es) | 2012-09-25 | 2013-09-25 | Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina. |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US9839703B2 (es) |
| EP (2) | EP2900279B1 (es) |
| JP (4) | JP6562838B2 (es) |
| KR (2) | KR102190005B1 (es) |
| AU (4) | AU2013323596C1 (es) |
| BR (1) | BR112015006453B1 (es) |
| CA (2) | CA2886068C (es) |
| DK (1) | DK2900279T3 (es) |
| ES (1) | ES2745635T3 (es) |
| HR (1) | HRP20191620T1 (es) |
| HU (1) | HUE045724T2 (es) |
| IL (4) | IL276300B1 (es) |
| LT (1) | LT2900279T (es) |
| MX (1) | MX362675B (es) |
| PL (1) | PL2900279T3 (es) |
| PT (1) | PT2900279T (es) |
| RU (1) | RU2693465C9 (es) |
| SI (1) | SI2900279T1 (es) |
| WO (1) | WO2014052471A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10449260B2 (en) * | 2011-07-08 | 2019-10-22 | Theodosia Maina-Nock | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| MX362675B (es) * | 2012-09-25 | 2019-01-30 | Advanced Accelerator Applications Usa Inc | Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina. |
| EP3015462A1 (en) * | 2014-10-29 | 2016-05-04 | OctreoPharm Schiences GmbH | Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals |
| EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
| US11857352B2 (en) | 2016-09-06 | 2024-01-02 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| WO2018096082A1 (en) | 2016-11-28 | 2018-05-31 | Bayer Pharma Aktiengesellschaft | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging |
| JP7084417B2 (ja) | 2017-01-12 | 2022-06-14 | ラジオメディックス インコーポレイテッド | 放射性同位体にキレートされたオクトレオチド誘導体を用いるソマトスタチン受容体を過剰発現しているがん細胞の治療 |
| AR116636A1 (es) * | 2018-10-12 | 2021-05-26 | Advanced Accelerator Applications Int Sa | Radiofármacos dirigidos a grpr y usos de los mismos |
| AU2019469641A1 (en) | 2018-11-13 | 2021-07-01 | Provincial Health Services Authority | Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders |
| MX2021006024A (es) | 2018-11-23 | 2021-07-06 | Bayer Ag | Formulacion de medios de contraste y proceso para prepararlos. |
| CA3154302A1 (en) * | 2019-09-16 | 2021-03-25 | Novartis Ag | Stable, concentrated radiopharmaceutical composition |
| TW202123975A (zh) * | 2019-09-17 | 2021-07-01 | 義大利商先進艾斯雷特應用（義大利）公司 | 放射性標記grpr拮抗劑之方法及其套組 |
| CN114728089A (zh) * | 2019-09-24 | 2022-07-08 | 诺华股份有限公司 | 用作治疗诊断剂的经放射性标记的grpr拮抗剂 |
| KR20220118464A (ko) * | 2019-12-19 | 2022-08-25 | 테크니쉐 우니베르지테트 뮌헨 | 암의 영상화 및 치료법을 위한 개선된 약동학을 갖는 화합물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019647A (en) | 1988-05-24 | 1991-05-28 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| US4943561A (en) | 1988-11-28 | 1990-07-24 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| US5028692A (en) * | 1989-04-25 | 1991-07-02 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| CA2045494A1 (en) | 1989-11-06 | 1991-05-07 | Luigia Gozzini | Reduced irreversible bombesin antagonists |
| CA2129032A1 (en) | 1992-02-07 | 1993-08-19 | Judson V. Edwards | Phenylalanine analogs of bombesin |
| US5620955A (en) | 1993-06-18 | 1997-04-15 | Peptide Technologies Corporation | Bombesin receptor antagonists and uses thereof |
| AU1172599A (en) | 1997-11-18 | 1999-06-07 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
| EP1654005A4 (en) | 2003-07-24 | 2011-06-15 | Bracco Imaging Spa | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR PREPARATION |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| JP2014500262A (ja) | 2010-11-22 | 2014-01-09 | ピラマル イメージング ソシエテ アノニム | 放射線治療のための１７７ルテチウム標識されたボンベシン類似体 |
| US10449260B2 (en) * | 2011-07-08 | 2019-10-22 | Theodosia Maina-Nock | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| MX362675B (es) * | 2012-09-25 | 2019-01-30 | Advanced Accelerator Applications Usa Inc | Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina. |
-
2013
- 2013-09-25 MX MX2015003772A patent/MX362675B/es active IP Right Grant
- 2013-09-25 JP JP2015534625A patent/JP6562838B2/ja active Active
- 2013-09-25 DK DK13815181.6T patent/DK2900279T3/da active
- 2013-09-25 HU HUE13815181A patent/HUE045724T2/hu unknown
- 2013-09-25 EP EP13815181.6A patent/EP2900279B1/en active Active
- 2013-09-25 KR KR1020157007572A patent/KR102190005B1/ko active IP Right Grant
- 2013-09-25 CA CA2886068A patent/CA2886068C/en active Active
- 2013-09-25 PT PT138151816T patent/PT2900279T/pt unknown
- 2013-09-25 US US14/431,096 patent/US9839703B2/en active Active
- 2013-09-25 ES ES13815181T patent/ES2745635T3/es active Active
- 2013-09-25 KR KR1020207034970A patent/KR102314293B1/ko active IP Right Grant
- 2013-09-25 PL PL13815181T patent/PL2900279T3/pl unknown
- 2013-09-25 AU AU2013323596A patent/AU2013323596C1/en active Active
- 2013-09-25 SI SI201331585T patent/SI2900279T1/sl unknown
- 2013-09-25 WO PCT/US2013/061712 patent/WO2014052471A1/en active Application Filing
- 2013-09-25 IL IL276300A patent/IL276300B1/en unknown
- 2013-09-25 IL IL312551A patent/IL312551A/en unknown
- 2013-09-25 CA CA3114832A patent/CA3114832A1/en active Pending
- 2013-09-25 RU RU2015115529A patent/RU2693465C9/ru active
- 2013-09-25 BR BR112015006453-1A patent/BR112015006453B1/pt active IP Right Grant
- 2013-09-25 EP EP19170067.3A patent/EP3536347A1/en active Pending
- 2013-09-25 LT LT13815181T patent/LT2900279T/lt unknown
-
2015
- 2015-03-19 IL IL237844A patent/IL237844B/en active IP Right Review Request
-
2017
- 2017-11-20 US US15/817,776 patent/US20180133349A1/en not_active Abandoned
- 2017-12-28 IL IL256649A patent/IL256649B/en active IP Right Grant
-
2018
- 2018-06-21 AU AU2018204513A patent/AU2018204513C1/en active Active
-
2019
- 2019-06-04 JP JP2019104379A patent/JP6997135B2/ja active Active
- 2019-08-16 AU AU2019216714A patent/AU2019216714B2/en active Active
- 2019-09-09 HR HRP20191620 patent/HRP20191620T1/hr unknown
- 2019-09-24 US US16/580,990 patent/US11083805B2/en active Active
-
2021
- 2021-03-26 AU AU2021201914A patent/AU2021201914A1/en active Pending
- 2021-07-23 US US17/383,567 patent/US20220008568A1/en active Pending
- 2021-07-23 US US17/383,577 patent/US20210346529A1/en active Pending
- 2021-07-23 US US17/383,550 patent/US20210346528A1/en active Pending
- 2021-09-22 JP JP2021154188A patent/JP7358430B2/ja active Active
-
2023
- 2023-07-13 JP JP2023115231A patent/JP2023126440A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015003772A (es) | Antagonistas de receptores de peptido liberadores de gastrina para la deteccion, diagnostico y tratamiento de cancer positivo a receptores de peptido liberadores de gastrina. | |
| MX2021008976A (es) | Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata. | |
| CY1122155T1 (el) | Συζευγμενες ενωσεις που περιλαμβανουν αντισωματα τροποποιημενης κυστεϊνης | |
| Koba et al. | Imaging devices for use in small animals | |
| AR081696A1 (es) | Anticuerpo para el diagnostico y/o pronostico de cancer | |
| GEP201706737B (en) | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy | |
| WO2010030120A3 (en) | Fluorescent silica nanoparticle with radioactive tag and the detecting method of pet and fluorescent dual imaging using thereof | |
| NZ710436A (en) | Biospecific agents for bone | |
| PH12018500701A1 (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
| BRPI1007117B8 (pt) | Método para a formação de imagem de ressonância magnética ou espectroscopia de ressonância magnética nuclear | |
| WO2013036607A3 (en) | Systems and methods for detecting the presence of anomalous material within tissue | |
| WO2016040458A3 (en) | Pet probes of radiofluorinated carboximidamides for ido-targeted imaging | |
| GB201317127D0 (en) | Optical imaging probes | |
| JP2012524029A5 (es) | ||
| Rostamzadeh et al. | Noninvasive Stem Cell Labeling Using USPIO Technique and their Detection with MRI | |
| MX336321B (es) | 99mtc-tat-bombesina como un nuevo radiofarmaco para la deteccion temprana de cancer de mama. | |
| Pinzón et al. | Radionecrosis versus progresión de la enfermedad en metástasis cerebrales: valor del 18F-DOPA PET/TC/RM | |
| Cozzone et al. | On the role of non conventional MRI techniques for human brain tumor characterization | |
| GB201315423D0 (en) | Paramagnetic metal labelled monoclonal antibody against Propionbacterium acnes for in vivo diagnostic using MRI or CT scan | |
| Bach et al. | A High Resolution Tractography Phantom | |
| Hamamura et al. | Publication Year: 2011 | |
| MX345185B (es) | NANOPARTICULAS DE ORO RADIOMARCADAS CON 177LU Y CONJUGADAS A PEPTIDOS C(RGDFK)C COMO UN NUEVO RADIOFARMACO PARA LA TERAPIA DE TUMORES QUE SOBRE-EXPRESAN INTEGRINAS A(V)ß(3). | |
| Choi et al. | Correlation of apparent diffusion coefficients measured by standard (1000 s/mm2) and high b-value (2000 s/mm2) diffusion MR imaging and SUV from FDG PET/CT in head and neck cancer | |
| Lu et al. | Inherent insensitivity to B1 field inhomogeneity using regularized nonlinear inversion reconstruction | |
| Mößle et al. | SQUID-detected microtesla MRI: a new modality for tumor detection? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |